Ruxolitinib Plus Azacitidine vs. Azacitidine Alone in Key Trials
The phase 3 MEDALIST trial (MEDAL-IST) directly compared ruxolitinib (a JAK1/JAK2 inhibitor) plus azacitidine against azacitidine monotherapy in 154 patients with higher-risk myelodysplastic syndromes (HR-MDS) and ring sideroblasts who failed or were ineligible for erythropoiesis-stimulating agents.[1] Median overall survival was 19.2 months with the combination versus 15.6 months with azacitidine alone (hazard ratio [HR] 0.75; 95% CI 0.52-1.10; p=0.14), missing statistical significance but showing a numerical benefit.[1][2]
Complete remission rates were higher with the combination (33.7% vs. 20.8%; p=0.03), as was the transfusion independence rate at week 24 (though exact figures varied by analysis).[1] Median duration of response was longer (18.7 months vs. 12.9 months).[2]
Outcomes in Subgroups and Secondary Endpoints
In patients with SF3B1 mutations (common in ring sideroblast MDS), the combination improved overall survival (HR 0.58; 95% CI 0.35-0.95).[1] Bone marrow blast reduction occurred more often (74.7% vs. 54.5%; p=0.01).[2] However, grade ≥3 infections were more frequent with ruxolitinib plus azacitidine (64% vs. 48%).[1]
No head-to-head trials exist in acute myeloid leukemia (AML); indirect comparisons from trials like SILO (ruxolitinib + azacitidine) suggest potential benefits, but these lack direct powering against azacitidine alone.[3]
Regulatory Approves and Real-World Data
The FDA approved ruxolitinib with azacitidine for HR-MDS in 2022 based on MEDALIST, expanding beyond its polycythemia vera and myelofibrosis indications.[4] Real-world studies report similar trends, with higher response rates (45-50% complete remission) but increased cytopenias.[5]
| Endpoint | Rux + Aza (n=78) | Aza Alone (n=76) | HR or P-value |
|----------|-------------------|------------------|---------------|
| Median OS | 19.2 months | 15.6 months | HR 0.75 (p=0.14) |
| CR Rate | 33.7% | 20.8% | p=0.03 |
| BM Blast Reduction | 74.7% | 54.5% | p=0.01 |
Why No OS Benefit Despite Response Gains?
The trial closed early due to futility on OS, possibly from competing risks in frail MDS patients or off-protocol therapies post-progression.[2] Ongoing trials like IMerge explore ruxolitinib monotherapy in lower-risk MDS, but combination data remains limited to MEDALIST.[6]
Sources
[1]: NEJM - MEDALIST Trial (2018)
[2]: JCO - Updated MEDALIST Analysis (2021)
[3]: Blood Advances - SILO Trial (2021)
[4]: FDA Approval Announcement (2022)
[5]: Leukemia - Real-World Rux/Aza Data (2023)
[6]: ClinicalTrials.gov - IMerge